These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

731 related items for PubMed ID: 16795969

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Usefulness of FDG-PET to detect recurrent cervical cancer based on asymptomatically elevated tumor marker serum levels--a preliminary report.
    Chang WC, Hung YC, Lin CC, Shen YY, Kao CH.
    Cancer Invest; 2004; 22(2):180-4. PubMed ID: 15199599
    [Abstract] [Full Text] [Related]

  • 23. Does CEA and CA 19-9 combined increase the likelihood of 18F-FDG in detecting recurrence in colorectal patients with negative CeCT?
    Panagiotidis E, Datseris IE, Rondogianni P, Vlontzou E, Skilakaki M, Exarhos D, Bamias A.
    Nucl Med Commun; 2014 Jun; 35(6):598-605. PubMed ID: 24681767
    [Abstract] [Full Text] [Related]

  • 24. Carcinoembryonic antigen directed PET-CECT scanning for postoperative surveillance of colorectal cancer.
    Vallam KC, Guruchannabasavaiah B, Agrawal A, Rangarajan V, Ostwal V, Engineer R, Saklani A.
    Colorectal Dis; 2017 Oct; 19(10):907-911. PubMed ID: 28444968
    [Abstract] [Full Text] [Related]

  • 25. Impact of 18F-FDG-positron emission tomography for decision making in colorectal cancer recurrences.
    Imdahl A, Reinhardt MJ, Nitzsche EU, Mix M, Dingeldey A, Einert A, Baier P, Farthmann EH.
    Langenbecks Arch Surg; 2000 Mar; 385(2):129-34. PubMed ID: 10796051
    [Abstract] [Full Text] [Related]

  • 26. Combined use of preoperative 18F FDG-PET imaging and intraoperative gamma probe detection for accurate assessment of tumor recurrence in patients with colorectal cancer.
    Sarikaya I, Povoski SP, Al-Saif OH, Kocak E, Bloomston M, Marsh S, Cao Z, Murrey DA, Zhang J, Hall NC, Knopp MV, Martin EW.
    World J Surg Oncol; 2007 Jul 16; 5():80. PubMed ID: 17634125
    [Abstract] [Full Text] [Related]

  • 27. Utility of 18-fluorodeoxyglucose positron emission/computed tomography in the management of recurrent colorectal cancer.
    Liong SY, Kochhar R, Renehan AG, Manoharan P.
    ANZ J Surg; 2012 Oct 16; 82(10):729-36. PubMed ID: 22989147
    [Abstract] [Full Text] [Related]

  • 28. Correlation between serum CEA level and metabolic volume as determined by FDG PET in postoperative patients with recurrent colorectal cancer.
    Choi MY, Lee KM, Chung JK, Lee DS, Jeong JM, Park JG, Kim JH, Lee MC.
    Ann Nucl Med; 2005 Apr 16; 19(2):123-9. PubMed ID: 15909492
    [Abstract] [Full Text] [Related]

  • 29. [Evaluation of efficacy and clinical impact of 18F-FDG-PET in the diagnosis of recurrent medullary thyroid cancer with increased calcitonin and negative imaging test].
    Gómez-Camarero P, Ortiz-de Tena A, Borrego-Dorado I, Vázquez-Albertino RJ, Navarro-González E, Ruiz-Franco-Baux JV, Cuenca-Cuenca JI.
    Rev Esp Med Nucl Imagen Mol; 2012 Sep 16; 31(5):261-6. PubMed ID: 23067528
    [Abstract] [Full Text] [Related]

  • 30. Diagnostic value of (18)F-FDG PET/CT as first choice in the detection of recurrent colorectal cancer due to rising CEA.
    Gade M, Kubik M, Fisker RV, Thorlacius-Ussing O, Petersen LJ.
    Cancer Imaging; 2015 Aug 13; 15(1):11. PubMed ID: 26263901
    [Abstract] [Full Text] [Related]

  • 31. Clinical impact of [(18)F]FDG-PET in patients with suspected recurrent breast cancer based on asymptomatically elevated tumor marker serum levels: a preliminary report.
    Liu CS, Shen YY, Lin CC, Yen RF, Kao CH.
    Jpn J Clin Oncol; 2002 Jul 13; 32(7):244-7. PubMed ID: 12324574
    [Abstract] [Full Text] [Related]

  • 32. Utility of 2-fluoro-2-deoxy-D-glucose positron emission tomography in managing patients of colorectal cancer with unexplained carcinoembryonic antigen elevation at different levels.
    Liu FY, Chen JS, Changchien CR, Yeh CY, Liu SH, Ho KC, Yen TC.
    Dis Colon Rectum; 2005 Oct 13; 48(10):1900-12. PubMed ID: 15991059
    [Abstract] [Full Text] [Related]

  • 33. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study.
    Langenhoff BS, Oyen WJ, Jager GJ, Strijk SP, Wobbes T, Corstens FH, Ruers TJ.
    J Clin Oncol; 2002 Nov 15; 20(22):4453-8. PubMed ID: 12431968
    [Abstract] [Full Text] [Related]

  • 34. Usefulness of fluoro-2-deoxyglucose positron emission tomography for investigating unexplained rising carcinoembryonic antigen levels that occur during the postoperative surveillance of lung cancer patients.
    Isobe K, Hata Y, Takai Y, Shibuya K, Takagi K, Homma S.
    Int J Clin Oncol; 2009 Dec 15; 14(6):497-501. PubMed ID: 19967484
    [Abstract] [Full Text] [Related]

  • 35. DIAGNOSTIC ROLE OF FLUORINE-18 (18F) FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY IN DETECTING RECURRENT DISEASE IN PATIENTS WITH COLORECTAL CANCER AND ELEVATED CARCINOEMBRYONIC ANTIGEN.
    Matovina E, Mihailović J, Nikoletić K, Srbovan D.
    Med Pregl; 2015 Dec 15; 68(11-12):376-81. PubMed ID: 26939303
    [Abstract] [Full Text] [Related]

  • 36. Role of FDG-PET in surgical management of patients with colorectal liver metastases.
    Teague BD, Morrison CP, Court FG, Chin VT, Costello SP, Kirkwood ID, Maddern GJ.
    ANZ J Surg; 2004 Aug 15; 74(8):646-52. PubMed ID: 15315564
    [Abstract] [Full Text] [Related]

  • 37. FDG PET and immunoscintigraphy with 99mTc-labeled antibody fragments for detection of the recurrence of colorectal carcinoma.
    Willkomm P, Bender H, Bangard M, Decker P, Grünwald F, Biersack HJ.
    J Nucl Med; 2000 Oct 15; 41(10):1657-63. PubMed ID: 11037995
    [Abstract] [Full Text] [Related]

  • 38. 18F-FDG PET/CT in the post-operative monitoring of patients with adrenocortical carcinoma.
    Ardito A, Massaglia C, Pelosi E, Zaggia B, Basile V, Brambilla R, Vigna-Taglianti F, Duregon E, Arena V, Perotti P, Penna D, Terzolo M.
    Eur J Endocrinol; 2015 Dec 15; 173(6):749-56. PubMed ID: 26346137
    [Abstract] [Full Text] [Related]

  • 39. Value of CT, FDG PET-CT and serum tumor markers in staging recurrent colorectal cancer.
    Caglar M, Yener C, Karabulut E.
    Int J Comput Assist Radiol Surg; 2015 Jul 15; 10(7):993-1002. PubMed ID: 25213271
    [Abstract] [Full Text] [Related]

  • 40. High incidence of peritoneal implants in recurrence of intra-abdominal cancer revealed by 18F-FDG PET/CT in patients with increased tumor markers and negative findings on conventional imaging.
    Panagiotidis E, Datseris IE, Exarhos D, Skilakaki M, Skoura E, Bamias A.
    Nucl Med Commun; 2012 Apr 15; 33(4):431-8. PubMed ID: 22293498
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 37.